Milk Thistle

• Amanita (death cap) mushroom poisoning, as intravenous silibinin in hospital, an established antidote use
• Non-alcoholic / metabolic-associated fatty liver disease, modest reductions in liver enzymes
• Alcoholic liver disease adjunct, historically common but not shown to change mortality
• Chronic hepatitis C, tested and found no better than placebo in the SyNCH trial
• Drug-induced liver stress, preliminary and inconsistent
• Diabetes glycemic support, early and unconfirmed

Milk thistle (Silybum marianum) is a Mediterranean thistle in the Asteraceae family (composites, including ragweed, chrysanthemum, daisy, relevant for allergic cross-reactivity) with one of the longest continuous medicinal uses of any plant for hepatic indications. Dioscorides documented milk thistle in De Materia Medica (1st century CE); Pliny the Elder described its use for "carrying off bile"; medieval European herbalists like Culpeper continued the hepatic application tradition. The Latin name reflects the persistent Christian legend that the white marbling on the leaves came from drops of the Virgin Mary's milk while nursing the infant Jesus during the flight to Egypt, the "Marian thistle" naming has persisted in multiple European languages. The seeds (technically achenes) contain the medicinal active compound complex; the spiny leaves and flowers, while traditionally documented, contain limited active compound content. The active compound profile centers on silymarin, a flavonolignan mixture extracted from the seeds. Silymarin is approximately 65-80% of total seed extract content in standardized preparations and contains six major flavonolignans: silybin A (also called silibinin A), silybin B, isosilybin A, isosilybin B, silychristin, and silydianin. Silybin (silibinin A+B combined) is the dominant and most pharmacologically characterized component, comprising approximately 40-60% of total silymarin. Beyond silymarin, the seeds contain additional flavonolignans, taxifolin, and various polyphenols. The pharmacology centers on multiple integrated mechanisms: (1) direct membrane stabilization of hepatocytes, preventing toxin entry through cell membrane interaction; (2) glutathione restoration and antioxidant support, particularly against oxidative damage from toxins and inflammation; (3) inhibition of leukotriene synthesis and TNF-alpha production, providing anti-inflammatory effects in hepatic tissue; (4) competition with toxin binding at hepatocyte membrane receptors, the foundational mechanism for the Amanita phalloides poisoning antidote application; (5) modulation of hepatic stellate cell activation and TGF-beta signaling, providing anti-fibrotic effects relevant to chronic liver disease. The Amanita phalloides (death cap mushroom) poisoning application is among the most pharmacologically credible: IV silibinin (Legalon SIL from Madaus/Mylan) is established antidote therapy globally, blocking hepatocyte uptake of amatoxin through competitive inhibition at OATP1B3 transporters. This pharmacological credibility anchors the broader consumer hepatoprotective category. The overwhelming practical challenge is bioavailability. Free silymarin has poor oral absorption (~20-50% intestinal absorption with extensive first-pass metabolism); silybin specifically has even more limited free bioavailability. Phytosome formulations (Siliphos from Indena, complexing silybin with phosphatidylcholine) provide 4-5-fold bioavailability enhancement at equivalent silybin dose. The Italian Legalon brand from Madaus (now Mylan/Viatris) provides pharmaceutical-grade standardization and clinical research inheritance. The 2012 HALT-C (Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis) Phase 2 trial of standardized silymarin in chronic hepatitis C showed NULL results, substantially recalibrating expectations about high-dose silymarin in chronic viral hepatitis. The NAFLD evidence base is more promising; cirrhosis evidence is mixed; the Amanita poisoning antidote remains the pharmaceutical gold standard application.

Standard milk thistle supplementation centers on 200-800mg/day of standardized silymarin (70-80% silymarin content from 70-80% standardized extract). Clinical trials cluster at 420mg/day silymarin (Ferenci 1989 alcoholic cirrhosis) and 200-600mg/day for NAFLD applications. The HALT-C 2012 trial used substantially higher doses (420mg or 700mg three times daily = 1260-2100mg/day silymarin) with null results, supporting that very high doses are not necessarily better. The IV silibinin Amanita poisoning protocol uses 5mg/kg loading dose followed by 20mg/kg/day infusion, pharmaceutical pharmacology requiring emergency department coordination. Take with food, fat-soluble flavonolignan absorption improves substantially with meal administration; the lipophilic chemistry favors lipid-rich meals. Silymarin phytosome (Siliphos) at 200-400mg/day provides equivalent silybin exposure to higher doses of standard standardized extracts due to 4-5x bioavailability enhancement; preferred for therapeutic applications where bioavailability matters. Treatment durations matter substantially, hepatic clinical effects typically develop over 8-12 weeks of consistent supplementation. The Upper Limit (UL) has not been formally established; doses above 1500mg/day silymarin produce diminishing returns with modest increased GI side effects (loose stools, mild abdominal discomfort). The form selection matters: phytosome (Siliphos) preferred for therapeutic positioning; standard 70-80% standardized extracts adequate for general hepatic support at modest premium pricing for phytosome; whole milk thistle seed adequate for traditional use but less reliable. Standardization specification matters substantially, non-standardized products vary enormously in active compound content. The species verification matters less than for many botanicals, Silybum marianum is the dominant cultivated species without substantial substitution concerns.

Standard silymarin range

200-800mg/day

NAFLD applications

200-600mg silymarin/day

Alcoholic cirrhosis (Ferenci protocol)

420mg silymarin/day

HALT-C hepatitis C dose (null result)

1260-2100mg silymarin/day

Phytosome (Siliphos)

200-400mg/day

IV silibinin Amanita protocol

5mg/kg loading + 20mg/kg/day infusion

Whole seed traditional

1-3g/day

Treatment duration for hepatic effects

8-12+ weeks

• Legalon (Madaus / Mylan Pharmaceutical Silymarin)

  Rating: gold

  German pharmaceutical-grade standardized silymarin extract (70-80% silymarin content). Foundational European pharmaceutical preparation with substantial clinical research inheritance including Ferenci 1989 cirrhosis trial. Available by prescription in Germany and select European markets; consumer supplement equivalents distributed by major Western brands. Premium pricing reflecting pharmaceutical-grade standardization.

• Siliphos / Silymarin Phytosome (Indena)

  Rating: gold

  Italian phytosome formulation combining silybin with phosphatidylcholine producing 4-5x improved silybin bioavailability versus standard silymarin extracts. Substantial Indena pharmaceutical research investment. Distributed by Thorne (Siliphos Silybin), Pure Encapsulations, and similar premium supplement brands. Premium pricing justified by bioavailability enhancement.

• Standardized Milk Thistle Extract (70-80% Silymarin)

  Rating: gold

  Standard concentrated extract specification used in most modern clinical trials. Major reputable manufacturers (NOW Foods, Thorne, Solgar, Nature's Way, Gaia Herbs) provide reliable standardized 70-80% silymarin products. Acceptable for most therapeutic applications.

• IV Silibinin (Legalon SIL)

  Rating: gold

  Pharmaceutical IV silibinin preparation specifically for Amanita phalloides (death cap mushroom) poisoning. Standard antidote therapy globally; substantial mortality reduction versus historical untreated controls. Specialist emergency medicine and hepatology coordination; not consumer supplement form.

• Whole Milk Thistle Seed

  Rating: good

  Whole dried milk thistle seeds without extraction concentration. Active compound content varies based on growing conditions, harvest timing, and processing. Reasonable for traditional preparation (decoction, ground seeds added to food) but substantially less reliable than standardized extracts for clinical effects.

• Milk Thistle Tincture (Liquid Extract)

  Rating: good

  Ethanolic extract preparation. Provides faster absorption than capsule forms; preferred for acute pre-toxin dosing in some traditional protocols. Standardization varies more across tincture products; reputable manufacturers specify silymarin content per dose.

• Milk Thistle + Comprehensive Liver Support Formulations

  Rating: good

  Milk thistle commonly included in comprehensive liver support formulations alongside NAC, alpha-lipoic acid, choline, dandelion, artichoke, and other hepatoprotective compounds. Mechanistically reasonable for users seeking comprehensive hepatic support; verify milk thistle dose specifically.

• Generic Non-Standardized Milk Thistle Products

  Rating: caution

  Products without specific silymarin content disclosure. Quality variability substantial; clinical effects unreliable due to active compound variation. Acceptable for traditional/herbal use; not preferred for therapeutic applications.

• Amanita phalloides (death cap mushroom) poisoning

  Strength of evidence for this group: strong

  IV silibinin (Legalon SIL) is established antidote therapy globally with substantial mortality reduction versus historical controls. Mechanism through competitive inhibition of amatoxin hepatocyte uptake at OATP1B3 transporters. Foundational pharmaceutical use case providing pharmacological credibility for broader hepatoprotective framework. Emergency medicine and hepatology coordination essential.

• NAFLD (non-alcoholic fatty liver disease)

  Strength of evidence for this group: modest

  Solhi 2014, Hadi 2018 meta-analysis, and multiple subsequent trials support silymarin 200-800mg/day for modest ALT and AST improvements in NAFLD. Effect sizes modest; reasonable adjunct to comprehensive NAFLD management (weight loss, dietary modification, metabolic management). Coordinate with hepatology for established NAFLD.

• Alcoholic liver disease (cirrhosis adjunct)

  Strength of evidence for this group: cautious

  Ferenci 1989 supported survival benefit in Child-Pugh A cirrhosis subset; subsequent trials have shown mixed results. Reasonable adjunct to comprehensive alcoholic liver disease management; not substitute for alcohol cessation. Coordinate with hepatology; effect sizes modest at best.

• Drug-induced hepatotoxicity protection

  Strength of evidence for this group: cautious

  Preliminary evidence for silymarin protection during chemotherapy, methotrexate, and other hepatotoxic medication use. Specialist coordination (oncology, rheumatology), coordinate with prescribing physician. Mechanism through glutathione restoration and direct membrane stabilization is mechanistically reasonable.

• Type 2 diabetes (glycemic adjunct)

  Strength of evidence for this group: modest

  Voroneanu 2016 meta-analysis supports modest HbA1c and fasting glucose improvements at standard silymarin doses. Effect sizes smaller than metformin; reasonable adjunct to standard diabetes management. Coordinate with endocrinology.

• Chronic hepatitis B and C

  Strength of evidence for this group: cautious

  HALT-C 2012 demonstrated null results for high-dose silymarin (420-700mg three times daily) in chronic hepatitis C. Earlier optimism substantially recalibrated. Modest preliminary evidence for ALT improvement in chronic hepatitis B; not substitute for established antiviral therapy. Coordinate with hepatology.

• Polycystic ovary syndrome (preliminary)

  Strength of evidence for this group: cautious

  Preliminary evidence for silymarin in PCOS metabolic markers. Effect sizes preliminary; reasonable adjunct to comprehensive PCOS management.

• Cancer adjunctive (preliminary)

  Strength of evidence for this group: cautious

  Preliminary evidence for silymarin in chemotherapy-induced hepatotoxicity protection and possibly direct antitumor effects. Specialist oncology coordination essential, coordinate with treating oncologist before initiation.

• Pregnancy and lactation

  Strength of evidence for this group: cautious

  Limited safety data for therapeutic supplementation in pregnancy. Some traditional galactagogue (lactation-supporting) use in nursing mothers; lactation safety appears acceptable at typical doses. Coordinate with OB-GYN and pediatrician.

• Asteraceae family allergies

  Strength of evidence for this group: avoid

  Allergic reactions in users with established Asteraceae family sensitivity (ragweed, chrysanthemum, daisy, marigold). Avoid milk thistle in users with known significant Asteraceae allergy.

• Healthy adults (general hepatic support)

  Strength of evidence for this group: cautious

  Reasonable component of comprehensive hepatic nutrition for users with specific risk factors (heavy alcohol use, medication-related liver stress, occupational hepatotoxin exposure). Effect sizes modest in healthy non-deficient users.

• NAC (N-Acetylcysteine)

  Interaction: synergy

  Mechanistically complementary hepatoprotection, NAC provides cysteine for glutathione synthesis; milk thistle supports membrane stabilization and direct antioxidant effects. Common combination in comprehensive liver support protocols. The "GSH precursor + hepatoprotective" framework is mechanistically integrated.

• Alpha-Lipoic Acid (ALA)

  Interaction: synergy

  Common combination in comprehensive hepatoprotective protocols. Mechanistically complementary, ALA provides direct antioxidant and metal chelation; milk thistle provides membrane stabilization.

• Choline / Phosphatidylcholine

  Interaction: synergy

  Mechanistically complementary, choline supports hepatic lipid export and membrane phospholipid synthesis; milk thistle provides membrane stabilization. Common combination in NAFLD protocols including the Loguercio 2007 phytosome-vitamin E trial framework.

• Statins

  Interaction: caution

  Theoretical CYP3A4 interaction, milk thistle modulates CYP3A4 activity (mixed inhibition and induction in different studies). May affect statin pharmacokinetics; coordinate with cardiology for users on statin therapy. Some clinicians use milk thistle adjunctively to reduce statin hepatotoxicity risk; coordinate rather than self-initiate.

• Calcium Channel Blockers

  Interaction: caution

  CYP3A4 substrate; potential pharmacokinetic interaction. Coordinate with prescribing physician for chronic combined use.

• Immunosuppressants (Cyclosporine, Tacrolimus)

  Interaction: caution

  CYP3A4 substrates with narrow therapeutic windows. Significant theoretical interaction concern; coordinate with transplant medicine specialist for combined use.

• Chemotherapy Agents

  Interaction: caution

  Mixed evidence for chemotherapy-milk thistle interactions. Coordinate with oncology, some specific protocols use milk thistle adjunctively for hepatotoxicity protection; others recommend avoidance due to theoretical interference.

• Hormone-Sensitive Cancers

  Interaction: caution

  Mild estrogenic activity at high doses warrants caution in users with current or history of breast cancer, ovarian cancer, endometrial cancer, or other hormone-sensitive cancers. Coordinate with oncology.

• Oral Contraceptives

  Interaction: caution

  Theoretical CYP3A4 interaction may affect oral contraceptive pharmacokinetics. Coordinate with prescribing physician for users on hormonal contraception.

• Iron Supplements

  Interaction: caution

  Theoretical iron chelation potential. Separate iron supplementation by 2+ hours if iron deficiency is a clinical concern.

• Asteraceae Family Allergies

  Interaction: avoid

  Allergic cross-reactivity with ragweed, chrysanthemum, daisy, marigold allergies. Avoid milk thistle in users with established significant Asteraceae allergy.

• Alcohol

  Interaction: synergy

  The most common practical "stack", milk thistle is often used for hepatic support in heavy alcohol users. Reasonable hepatoprotective adjunct; emphatically not substitute for alcohol cessation in established alcohol use disorder.

Look for: explicit Silybum marianum species specification; standardization to specific silymarin content (70-80% silymarin standard); identification of dominant silybin content if specified; Siliphos branding for phytosome formulations; Legalon heritage for pharmaceutical-grade positioning; USP or NSF third-party verification; reputable manufacturer with quality control disclosure. Avoid: products without silymarin content standardization; generic "milk thistle" products without specific extract specification; products at unusually low cost (likely quality compromise); proprietary "liver detox blends" obscuring milk thistle dose; products marketed with aggressive cancer cure or hepatitis cure claims that exceed evidence base.

Research published from: Mediterranean.

Milk thistle's medicinal use extends more than two thousand years across Mediterranean and European traditions. Dioscorides documented Silybum marianum in De Materia Medica (1st century CE) for hepatic and biliary indications; Pliny the Elder described its use for "carrying off bile" in Natural History. Medieval European herbalists including Hildegard von Bingen, John Gerard, and Nicholas Culpeper continued the hepatic application tradition with substantial documentation. The Christian "Marian thistle" legend explaining the leaf marbling pattern established cultural-religious framing that persisted through European traditional medicine. The modern pharmacological era began in 1968 with German researchers at Madaus AG isolating silymarin from milk thistle seeds and characterizing the flavonolignan complex. The Madaus pharmaceutical development culminated in Legalon, pharmaceutical-grade standardized silymarin preparation that became established in German and European hepatic medicine. The 1969 introduction of Legalon marked the modern pharmaceutical era; subsequent development produced IV silibinin formulation (Legalon SIL) specifically for Amanita phalloides poisoning treatment. The Amanita antidote era developed substantially through the 1970s-1990s. Mengs, Magdalan, and colleagues characterized the pharmacological mechanism, competitive inhibition of amatoxin uptake at hepatocyte OATP1B3 transporters. IV silibinin became established antidote therapy globally; the substantial mortality reduction in Amanita poisoning provides foundational pharmacological credibility for the broader hepatoprotective category. The European clinical trial era developed through the 1980s-2000s with Ferenci 1989 J Hepatol alcoholic cirrhosis trial foundational, Saller 2001 Drugs systematic review consolidating evidence, and multiple subsequent trials in alcoholic liver disease, NAFLD, chronic hepatitis, and drug-induced hepatotoxicity. Italian Loguercio 2007 phytosome-comprehensive trial extended the evidence base into combination formulations. The Italian Indena phytosome development era extended through the 1990s-2000s with development of Siliphos (silybin phytosome) providing 4-5x bioavailability enhancement. The phytosome category created premium clinical-grade positioning that has expanded substantially through Western consumer supplement markets. The HALT-C trial era brought rigorous US NIH-funded research to chronic hepatitis C application. The 2012 Fried JAMA publication documented null results for high-dose silymarin in hepatitis C, substantially recalibrating earlier optimism about milk thistle in chronic viral hepatitis. The null result has produced more nuanced clinical guidance about specific application contexts. The NAFLD evidence era has matured through the 2010s-2020s with Solhi 2014, Hadi 2018 meta-analysis, and multiple subsequent trials supporting modest hepatic marker improvements. The NAFLD application has emerged as the most-evidenced modern consumer supplement use case. The consumer supplement market has matured substantially through the 2000s-2020s with milk thistle becoming among the most-purchased liver health supplements globally. The category continues to evolve with phytosome and pharmaceutical-grade positioning, NAFLD-focused marketing, and ongoing pharmacovigilance for drug interactions and allergic reactions.

1. 1st century CEDioscorides De Materia Medica documentation
2. Pliny the ElderNatural History hepatic use documentation
3. Medieval eraHildegard von Bingen, Gerard, Culpeper European herbal tradition
4. 1968Madaus AG isolates silymarin and characterizes flavonolignan complex
5. 1969Legalon pharmaceutical introduction (Germany)
6. 1970s-1990sIV silibinin development and Amanita antidote establishment
7. 1989Ferenci alcoholic cirrhosis foundational trial (J Hepatol)
8. 1990sIndena Siliphos phytosome development
9. 2001Saller systematic review (Drugs)
10. 2007Loguercio cirrhosis phytosome-comprehensive trial
11. 2012HALT-C trial null result for hepatitis C (Fried, JAMA); Mengs Amanita IV silibinin mechanism (J Pharmacol Exp Ther)
12. 2014Solhi NAFLD trial
13. 2016Voroneanu diabetes meta-analysis
14. 2017Federico phytosome bioavailability characterization
15. 2018Hadi NAFLD meta-analysis

• Whether enhanced bioavailability formulations (Siliphos phytosome) produce clinically meaningful advantages over standard standardized extracts at equivalent total silymarin dose in head-to-head clinical outcome trials, bioavailability differences are clear but clinical outcome translation is less rigorously established.
• Whether the HALT-C 2012 null result for chronic hepatitis C generalizes to other chronic viral hepatitis contexts or specific subpopulations who might still benefit.
• Whether milk thistle has specific applications in drug-induced hepatotoxicity protection (acetaminophen, methotrexate, antineoplastic agents) beyond preliminary evidence and theoretical mechanism support.
• Whether the cardiovascular evidence (Voroneanu 2016 diabetes) translates to broader metabolic syndrome applications or specific subpopulations.
• Whether the cancer adjunctive evidence (chemotherapy hepatotoxicity protection, possibly direct antitumor effects) will mature into oncology integration or remain specialist alternative consideration.
• How best to integrate milk thistle with established NAFLD management, the Hadi 2018 meta-analysis supports adjunctive use but mainstream hepatology guidelines do not typically include milk thistle.
• Whether genetic variants affecting silymarin metabolism (CYP3A4 variants, UGT variants) produce individual variability in clinical response.
• Whether the Asteraceae family allergy cross-reactivity is consistent across all silymarin preparations or varies by extraction methodology.

Universally available globally as dietary supplement and pharmaceutical product. Legal under DSHEA in the United States and equivalent supplement regulations in most jurisdictions. Not on WADA prohibited list. Pharmaceutical preparations: Legalon (Madaus/Mylan/Viatris, Germany) is the foundational pharmaceutical-grade silymarin standard available by prescription in Germany and select European markets; IV Legalon SIL (silibinin) is established Amanita phalloides antidote globally. Major retail supplement brands include NOW Foods, Thorne (Siliphos Silybin), Pure Encapsulations, Designs for Health, Gaia Herbs, Solgar, Nature's Way, Life Extension, and many liver-focused supplement brands. Indena S.p.A. (Italy) maintains Siliphos phytosome trademark and licenses to premium supplement brands globally. Madaus heritage products (now Mylan/Viatris) provide pharmaceutical-grade Legalon equivalents in European and supplement markets. Production is widely distributed, milk thistle is cultivated across Europe (particularly Germany, Hungary, Romania), the United States, China, Argentina, and other temperate regions. The plant is also an invasive weed in many regions, providing substantial agricultural supply. Quality variation across brands depends substantially on standardization specification and processing quality; third-party testing (USP, NSF) provides standard quality assurance. The Asteraceae family allergy cross-reactivity creates specific population subgroup where avoidance is recommended; otherwise universally accessible.

Status current as of July 2026. Regulatory positions change, sometimes quickly.

Species

Silybum marianum (St. Mary's thistle, Marian thistle)

Family

Asteraceae (composites, allergic cross-reactivity)

Active compound class

Silymarin (flavonolignan mixture)

Dominant compound

Silybin (silibinin A+B, ~40-60% of silymarin)

Standardization

70-80% silymarin standard

Standard dose

200-800mg silymarin/day

What follows is unfinished work on our side, not a finding about Milk Thistle. A short entry is not a safe entry.

• Cost and market. We have not documented what it sells for or who sells it.
• Supply chain. We have not mapped where it is made.
• Who uses it. We have not documented the user groups.
• What could change. No forward-looking summary yet.
• How it compares. We have not set it against the alternatives.
• Children and teenagers. We have not checked what is known about younger people.
• Where we land. We have not taken a position on this yet.